

BBL CRYSTAL™ IDENTIFICATION SYSTEMS

GRAM-POSITIVE ID KIT

CLIA COMPLEXITY: HIGH

CDC IDENTIFIER CODES

ANALYTE: 0412

TEST SYSTEM: 07919

INTENDED USE

The **BBL CRYSTAL™** Gram-Positive (GP) Identification (ID) system is a miniaturized identification method employing modified conventional, fluorogenic and chromogenic substrates. It is intended for the identification of aerobic gram-positive bacteria.^{1,2,13,16}

SUMMARY AND EXPLANATION

Micromethods for the biochemical identification of microorganisms were reported as early as 1918.³ Several publications reported on the use of the reagent-impregnated paper discs and micro-tube methods for differentiating enteric bacteria.^{3,4,7,17,19} The interest in miniaturized identification systems led to the introduction of several commercial systems in the late 1960s, and they provided advantages in requiring little storage space, extended shelf life, standardized quality control and ease of use.

In general, many of the tests used in the **BBL CRYSTAL** ID Systems are modifications of classical methods. These include tests for fermentation, oxidation, degradation and hydrolysis of various substrates. In addition, there are chromogen and fluorogen linked substrates, as in the **BBL CRYSTAL** GP ID panel, to detect enzymes that microbes use to metabolize various substrates.^{5,7,8,9,11,12,14,15}

The **BBL CRYSTAL™** GP ID kit is comprised of (i) **BBL CRYSTAL** GP ID panel lids, (ii) **BBL CRYSTAL** bases and (iii) **BBL CRYSTAL™** ANR, GP, RGP, N/H ID Inoculum Fluid (IF) tubes. The lid contains 29 dehydrated substrates and a fluorescence control on tips of plastic prongs. The base has 30 reaction wells. Test inoculum is prepared with the inoculum fluid and is used to fill all 30 wells in the base. When the lid is aligned with the base and snapped in place, the test inoculum rehydrates the dried substrates and initiates test reactions.

Following an incubation period, the wells are examined for color changes or presence of fluorescence that result from metabolic activities of the microorganisms. The resulting pattern of the 29 reactions is converted into a ten-digit profile number that is used as the basis for identification.¹⁸ Biochemical and enzymatic reaction patterns for the 29 **BBL CRYSTAL** GP ID substrates for a wide variety of microorganisms are stored in the **BBL CRYSTAL** GP ID database. A complete list of taxa that comprises the current database is provided in **Table 1**.

PRINCIPLES OF THE PROCEDURE

The **BBL CRYSTAL** GP ID panels contain 29 dried biochemical and enzymatic substrates. A bacterial suspension in the inoculum fluid is used for rehydration of the substrates. The tests used in the system are based on microbial utilization and degradation of specific substrates detected by various indicator systems. Enzymatic hydrolysis of fluorogenic substrates containing coumarin derivatives of 4-methylumbelliferone (4MU) or 7-amino-4-methylcoumarin (7-AMC), results in increased fluorescence that is easily detected visually with a UV light source.^{11,12,14,15} Chromogenic substrates upon hydrolysis produce color changes that can be detected visually. In addition, there are tests that detect the ability of an organism to hydrolyze, degrade, reduce or otherwise utilize a substrate in the **BBL CRYSTAL** ID Systems.

Reactions employed by various substrates and a brief explanation of the principles employed in the system are described in **Table 2**. Panel location in referred tables indicates the row and column where the well is located (example: 1J refers to Row 1 in column J).

REAGENTS

The **BBL CRYSTAL** GP ID panel contains 29 enzymatic and biochemical substrates. Refer to **Table 3** for a list of active ingredients.

Precautions: *in vitro* Diagnostic

After review by the U.S. Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) under CLIA '88, this product has been identified as high complexity. The CDC Analyte Identifier Code is 0412; the CDC Test System Identifier Code is 07919.

After use, all infectious materials including plates, cotton swabs, inoculum fluid tubes, and panels must be autoclaved prior to disposal or incineration.

STORAGE AND HANDLING/SHELF LIFE

Lids: **BBL CRYSTAL** GP lids are individually packaged and must be stored unopened in a refrigerator at 2 - 8° C. DO NOT FREEZE. Visually inspect the package for holes or cracks in the foil package. Do not use if the packaging appears to be damaged. Lids in the original packaging, if stored as recommended, will retain expected reactivity until the date of expiration.

Bases: Bases are packaged in two sets of ten, in **BBL CRYSTAL** incubation trays. The bases are stacked facing down to minimize air contamination. Store in a dust-free environment at 2 - 30° C, until ready to use. Store unused bases in the tray, in plastic bag. Empty trays should be used to incubate inoculated panels.

Inoculum Fluid: **BBL CRYSTAL** ANR, GP, RGP, N/H ID Inoculum Fluid (IF) is packaged in two sets of ten tubes. Visually inspect the tubes for cracks, leaks, etc. Do not use if there appears to be a leak, tube or cap damage or visual evidence of contamination (i.e., haziness, turbidity). Store

tubes at 2 - 25°C. Expiration dating is shown on the tube label. Only ANR, GP, RGP, N/H Inoculum Fluid should be used with **BBL CRYSTAL GP ID** panels.

On receipt, store the **BBL CRYSTAL GP ID** kit at 2 - 8°C. Once opened, only the lids need to be stored at 2 - 8°C. The remaining components of the kit may be stored at 2 - 25°C. If the kit or any of the components are stored refrigerated, each should be brought to room temperature prior to use.

SPECIMEN COLLECTION AND PROCESSING

BBL CRYSTAL ID Systems are **not** for use directly with clinical specimens. Use isolates from media such as **Trypticase™** Soy Agar with 5% Sheep Blood (**TSA II™**) or Columbia Agar with 5% Sheep Blood (Columbia Blood Agar). Use of selective media such as Phenylethyl Alcohol Agar with 5% Sheep Blood (PEA) or Columbia CNA Agar with 5% Sheep Blood (CNA) is also acceptable. Media containing esculin should not be used. The test isolate must be a pure culture, no more than 18 - 24 hours old for most genera; for some slow growing organisms up to 48 hours may be acceptable. When swabs are utilized, only cotton-tipped applicators should be used to prepare the inoculum suspensions. Some polyester swabs may cause problems with inoculation of the panels. (See “Limitations of the Procedure”.)

The incubator used should be humidified to prevent evaporation of fluid from the wells during incubation. The recommended humidity level is 40 - 60%. The usefulness of **BBL CRYSTAL ID** Systems or any other diagnostic procedure performed on clinical specimens is directly influenced by the quality of the specimens themselves. It is strongly recommended that laboratories employ methods discussed in the *Manual of Clinical Microbiology* for specimen collection, transport and inoculation onto primary isolation media.^{1,16}

TEST PROCEDURE

Materials Provided: BBL CRYSTAL GP ID Kit -

20 **BBL CRYSTAL GP ID** Panel Lids,

20 **BBL CRYSTAL** Bases,

20 **BBL CRYSTAL ANR, GP, RGP, N/H ID IF** Tubes. Each tube has approximately 2.3 ± 0.15 ml of Inoculum Fluid containing: KCl 7.5 g, CaCl₂ 0.5 g, Tricine N-[2-Hydroxy- 1, 1- bis (hydroxymethyl) methyl] glycine 0.895 g, purified water to 1000 ml,

2 incubation trays,

1 **BBL CRYSTAL** Results Pad.

Materials Not Provided: Sterile cotton swabs (*do not use polyester swabs*), incubator (35 - 37°C) non-CO₂ (40-60% humidity), McFarland No. 0.5 standard, **BBL CRYSTAL** Panel Viewer (includes **BBL CRYSTAL** Color Reaction Charts), **BBL CRYSTAL ID** System Electronic Codebook or **BBL CRYSTAL** Gram-Positive Manual Codebook, and appropriate culture media.

Also required are the necessary equipment and labware used for preparation, storage and handling of clinical specimens.

Test Procedure: BBL CRYSTAL GP ID System requires a Gram stain.

1. Remove lids from pouch. Discard desiccant. Once removed from the pouch, covered lids should be used within 1 h. Do not use the panel if there is no desiccant in the pouch.
2. Take an inoculum fluid tube and label with patient's specimen number. Using aseptic technique, pick colonies of the same morphology with the tip of a sterile cotton swab (*do not use a polyester swab*) or a wooden applicator stick from one of the recommended media (see section under "Specimen collection and Processing").
3. Suspend colonies in a tube of **BBL CRYSTAL ANR, GP, RGP, N/H ID Inoculum Fluid**.
4. Recap tube and vortex for approximately 10 - 15 sec. The turbidity should be equivalent to a McFarland No. 0.5 standard. If the inoculum suspension concentration is in excess of the recommended McFarland standard, one of the following steps is recommended:
 - a. Use a fresh tube of inoculum fluid to prepare a new inoculum suspension equivalent to a McFarland No. 0.5 standard.
 - b. If additional colonies are unavailable for preparation of a new inoculum suspension, using aseptic techniques, dilute the inoculum by adding the minimum required volume (not to exceed 1.0 ml) of 0.85% sterile saline or inoculum fluid to bring down the turbidity equivalent to a McFarland No. 0.5 standard. Remove the excess amount added to the tube with a sterile pipette so that the final volume of inoculum fluid is approximately equivalent to that of the original volume in the tube (2.3 ± 0.15 ml). Failure to make this adjustment in volume will result in spilling of the inoculum suspension over the black portion of the base rendering the panel unusable.
5. Take a base, and mark the patient's specimen number on the side wall.
6. Pour entire contents of the inoculum fluid tube into target area of the base.
7. Hold base in both hands and roll inoculum gently along the tracks until all of the wells are filled. Roll *back* any excess fluid to the target area and place the base on the bench top.
8. Align the lid so that the labeled end of the lid is on top of the target area of the base.
9. Push down until a slight resistance is felt. Place thumb on edge of lid towards middle of panel on each side and push downwards simultaneously until the lid snaps into place (listen for two "clicks").

Purity Plate: Using a sterile loop, recover a small drop from the inoculum fluid tube either before or after inoculating the base and inoculate an agar slant or plate (any appropriate medium) for purity

check. Discard inoculum fluid tube and cap in a biohazard disposal container. Incubate the slant or plate for 24 - 48 h at 35 - 37°C under appropriate conditions. The purity plate or slant may also be used for any supplementary tests or serology, if required.

Incubation: Place inoculated panels in incubation trays. Ten panels can fit in one tray (5 rows of 2 panels). All panels should be incubated **face down** (larger windows facing up; label facing down) in a non - CO₂ incubator with 40 - 60% **humidity**. Trays should not be stacked more than two high during incubation. The incubation time for panels is 18 - 24 h at 35 - 37°C. If panels are incubated for 24 h, they should be read within 30 min after removing from the incubator.

Reading: After the recommended period of incubation, remove the panels from the incubator. All panels should be read **face down** (larger windows up; label facing down) using the **BBL CRYSTAL** Panel Viewer. Refer to the color reaction chart and/or **Table 3** for an interpretation of the reactions. Use the results pad to record reactions.

- a. Read columns E thru J first, using the regular (white) light source.
- b. Read columns A thru D (fluorescent substrates) using the UV light source in the panel viewer. A fluorescent substrate well is considered positive *only if* the intensity of the fluorescence observed in the well is *greater* than the Negative Control well. (4A).

Calculation of BBL CRYSTAL Profile Number: Each test result (except 4A, which is used as a fluorescent negative control) scored positive is given a value of 4, 2, or 1, corresponding to the row where the test is located. A value of 0 (zero) is given to any negative result. The values resulting from each column are then added together. A 10 - digit number is generated; this is the profile number.

Example:	A	B	C	D	E	F	G	H	I	J
4	*	+	-	-	+	+	+	-	+	-
2	-	+	+	+	-	+	-	+	+	-
1	+	-	+	-	+	-	-	+	+	-
Profile	1	6	3	2	5	6	4	3	7	0

* (4A) = fluorescent negative control

The resulting profile number and cell morphology, if known, should be entered on a PC in which the **BBL CRYSTAL** ID System Electronic Codebook has been installed to obtain the identification. A Manual Codebook is also available. If a PC is not available contact Becton Dickinson Microbiology Systems Technical Services for assistance with identification.

QUALITY CONTROL

User Quality Control: Quality control testing is recommended for each lot of panels as follows -

1. Inoculate panel with *Streptococcus pyogenes* ATCC® 19615 per recommended procedure (refer to “Test Procedure”).
2. Incubate panel for 18-20 h at 35-37°C.
3. Read panel with panel viewer and color reaction chart; record reactions using the results pad. Alternatively, read the panel on the BBL Crystal AutoReader.
4. Compare recorded reactions with those listed in **Table 4**. If discrepant results are obtained, confirm purity of quality control strain before contacting Becton Dickinson Microbiology Systems Technical Services.

Expected test results for additional quality control test strains are listed in **Table 5**.

LIMITATIONS OF THE PROCEDURE

The **BBL CRYSTAL** GP ID System is designed for the taxa provided. Taxa other than those listed in Table 1 are not intended for use in this system.

The **BBL CRYSTAL** GP ID System database includes some species that are rarely isolated from human clinical specimens and were not encountered in the clinical studies of this product. It also includes some species that were encountered less than 10 times in the clinical studies. Refer to **Table 1** for a breakdown of the number of strains per species tested in clinical trials. The laboratorian should determine if additional testing is required to confirm identity of those species for which performance has not been established (i.e., those species where less than 10 isolates were evaluated in the clinical trials for this product).

The **BBL CRYSTAL** GP ID database was developed with **BBL™** brand media. Reactivity of some substrates in miniaturized identification systems may be dependant upon the source media used in inoculum preparations. We recommend the use of the following media for use with the **BBL CRYSTAL** GP ID System: **TSA II** and Columbia Blood Agar. Use of selective media, such as PEA or CNA, is also acceptable. Media containing esculin should not be used.

BBL CRYSTAL Identification Systems use a modified microenvironment; therefore, expected values for its individual tests may differ from information previously established with conventional test reactions. The accuracy of the **BBL CRYSTAL** GP ID System is based on statistical use of specially designed tests and an exclusive database.

While **BBL CRYSTAL** GP ID System aids in microbial differentiation, it should be recognized that minor variations may exist in strains within species. Use of panels and interpretation of results require a competent microbiologist. The final identification of the isolate should take into consideration the source of the specimen, aerotolerance, cell morphology, colonial characteristics on various media as well as metabolic end products as determined by gas-liquid chromatography, when warranted.

Only cotton-tipped applicator swabs should be used to prepare the inoculum suspension as some polyester swabs may cause the inoculum fluid to become viscous. This may result in insufficient inoculum fluid to fill the wells. Covered lids once removed from the sealed pouches must be used within 1 h to ensure adequate performance.

The incubator where panels are placed should be humidified to prevent evaporation of inoculum fluid from the wells during incubation. The recommended humidity level is 40 - 60%.

The panels, after inoculation, should only be incubated face down (larger windows facing up; label facing down) to maximize the effectiveness of substrates.

If the **BBL CRYSTAL** test profile yields a “No identification” result and culture purity has been confirmed, then it is likely that (i) the test isolate is producing *atypical BBL CRYSTAL reactions* (which may also be caused by procedural errors), (ii) the test species is not part of the intended taxa or (iii) the system is unable to identify the test isolate with the required level of confidence. Conventional test methods are recommended when user error has been ruled out.

EXPECTED VALUES

The expected substrate reactions for the species of organisms most frequently encountered in the clinical study of **BBL CRYSTAL GP ID System** are shown in **Table 6**. The provided percentages were generated from reactions given by the organisms used in generating the database. **Table 1** shows all the taxa tested during database generation.

PERFORMANCE CHARACTERISTICS

Reproducibility: In an external study involving four clinical laboratories, (total of four evaluations), the reproducibility of **BBL CRYSTAL GP ID substrates’** (29) reactions was studied by replicate testing. The reproducibility of the individual substrate reactions ranged from 79.2% - 100%. The overall reproducibility of **BBL CRYSTAL GP ID panel** was determined to be 96.7%.²⁰

Accuracy of Identification: The performance of **BBL CRYSTAL GP ID System** was compared to currently available commercial systems. A total of four studies were conducted in four independent laboratories. Fresh, routine isolates arriving in the clinical laboratory, as well as previously identified isolates of the clinical trial sites’ choice, were utilized to establish performance characteristics.

Out of 735 total isolates tested from the four studies using **BBL CRYSTAL GP Identification System**, 623 (84.8%) were correctly identified without the use of supplement tests, and 668 (90.9%) were correctly identified when supplemental tests were included. A total of 56 (7.6%) isolates were incorrectly identified, and a message of “No Identification” was obtained for 11 (1.5%) isolates.²⁰ **Table 7** shows the accuracy of identification for the species most frequently encountered (i.e., 10 or more isolates) in the clinical trial as well as for the remaining group of species where less than 10 isolates were tested.

AVAILABILITY

Cat. No. Description

- 245240 **BBL CRYSTAL™** Gram - Positive ID Kit, containing 20 each: **BBL CRYSTAL** GP ID Panel Lids, **BBL CRYSTAL** Bases and **BBL CRYSTAL** ANR, GP, RGP, N/H ID Inoculum Fluid.
- 245038 **BBL CRYSTAL™** ANR, GP, RGP, N/H ID Inoculum Fluid, ctn. of 10.
- 245031 **BBL CRYSTAL™** Panel Viewer, Domestic model, 110 V, 60 Hz.
- 245032 **BBL CRYSTAL™** Panel Viewer, European model, 220 V, 50 Hz.
- 245033 **BBL CRYSTAL™** Panel Viewer, Japanese model, 100 V, 50/60 Hz.
- 245034 **BBL CRYSTAL™** Panel Viewer, Longwave UV Tube.
- 245036 **BBL CRYSTAL™** Panel Viewer, White Light Tube.
- 441010 **BBL CRYSTAL™** ID System Electronic Codebook.
- 245037 **BBL CRYSTAL™** Identification Systems Gram - Positive Manual Codebook.
- 221165 **BBL™** Columbia Agar with 5% Sheep Blood, pkg. of 20.
- 221353 **BBL™** Columbia Agar with 5% Sheep Blood, ctn. of 100.
- 221352 **BBL™** Columbia CNA Agar with 5% Sheep Blood, pkg. of 20.
- 221353 **BBL™** Columbia CNA Agar with 5% Sheep Blood, ctn. of 100.
- 221179 **BBL™** Phenylethyl Alcohol Agar with 5% Sheep Blood, pkg. of 20.
- 221277 **BBL™** Phenylethyl Alcohol Agar with 5% Sheep Blood, ctn. of 100.
- 221239 **BBL™ Trypticase™** Soy Agar with 5% Sheep Blood (**TSA II™**), pkg. of 20.
- 221261 **BBL™ Trypticase™** Soy Agar with 5% Sheep Blood (**TSA II™**), ctn. of 100.
- 212539 **BBL™** Gram Stain Kit, pkg. of 4 x 250 ml bottles.

REFERENCES

1. Balows, A., W. J. Hausler, Jr., K.L. Herrmann, H.D. Isenberg, and H. J. Shadomy (ed). 1991. Manual of Clinical Microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
2. Baron, E.J., L.R. Peterson, and S.M. Finegold. 1994. Bailey and Scott's diagnostic microbiology, 9th ed. Mosby-Year Book, Inc., St. Louis.
3. Bronfenbrenner, J., and M. J. Schlesinger, 1918. A rapid method for the identification of bacteria fermenting carbohydrates. Am. J. Public Health. 8:922 - 923.
4. Cowan, S. T., and K. J. Steel. 1974. Manual for the identification of medical bacteria. 2nd ed. Cambridge University Press, Cambridge.
5. Edberg, S. C., and C. M. Kontnick. 1986. Comparison of β -glucuronidase-based substrate systems for identification of *Escherichia coli*. J. Clin. Microbiol. 24:368 - 371.
6. Ferguson, W. W., and A. E. Hook. 1943. Urease activity of *Proteus* and *Salmonella* organisms. J. Lab. Clin. Med. 28:1715 - 1720.
7. Hartman, P. A. 1968. Miniaturized microbiological methods. Academic Press, New York.
8. Kampfer, P., O. Rauhoff, and W. Dott 1991. Glycosidase profiles of members of the family *Enterobacteriaceae*. J. Clin. Microbiol. 29:2877 - 2879.
9. Killian, M., and P. Bulow. 1976. Rapid diagnosis of *Enterobacteriaceae* 1: detection of bacterial glycosidases. Acta Pathol. Microbiol. Scand. Sect. B. 84:245 - 251.
10. MacFaddin, J. F. 1980. Biochemical tests for identification of medical bacteria. 2nd. ed. Williams & Wilkins, Baltimore.
11. Maddocks, J. L., and M. Greenan. 1975. Rapid method for identifying bacterial enzymes. J. Clin. Pathol. 28:686-687.
12. Manafi, M., W. Kneifel, and S. Bascomb. 1991. Fluorogenic and chromogenic substrates used in bacterial diagnostics. Microbiol. Rev. 55:335 - 348.
13. Mandell, G. L., R. G. Douglas, Jr. and J. E. Bennett. 1990. Principles and practice of infectious diseases, 3rd ed. Churchill Livingstone Inc., New York.
14. Mangels, J., I. Edvalson, and M. Cox. 1993. Rapid Identification of *Bacteroides fragilis* group organisms with the use of 4-methylumbelliferone derivative substrates. Clin. Infect. Dis. 16(54):5319-5321.

15. Moncia, B. J., P. Braham, L. K. Rabe, and S. L. Hiller. 1991. Rapid presumptive identification of black-pigmented gram-negative anaerobic bacteria by using 4-methylumbelliferone derivatives. *J. Clin. Microbiol.* 29: 1955-1958.
16. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Tenover (ed.). 1995. *Manual of clinical microbiology*, 6th ed. American Society for Microbiology, Washington, D.C.
17. Sanders, A. C., J. E. Faber, and T. M. Cook. 1957. A rapid method for the characterization of enteric pathogen using paper discs. *Appl. Microbiol.* 5:36-40.
18. Sneath, P. H. A. 1957. The application of computers to taxonomy. *J. Gen. Microbiol.* 17:201-221.
19. Soto, O. B. 1949. Fermentation reactions with dried paper discs containing carbohydrate and indicator. *Puerto Rican J. Public Health. Trop. Med.* 25:96-100.
20. Data on file at Becton Dickinson Microbiology Systems.

TECHNICAL INFORMATION: In the United States, telephone Becton Dickinson Microbiology Systems Technical Services, toll free (800) 638-8663, selection 2.

Rev. 7/02 (PI 5/99)

© 2002 BD

BBL, BBL CRYSTAL, and Trypticase are trademarks of Becton, Dickinson and Company.

ATCC is a trademark of the American Type Culture Collection.

Approved by:

Date effective:

Supervisor

Date

Director

Date

Reviewed by:

Table 1

Taxa in BBL CRYSTAL™ GP ID System			
<i>Actinomyces pyogenes</i>	<i>Enterococcus durans</i> (2)	<i>Pediococcus dammosus</i>	<i>Streptococcus agalactiae</i>
<i>Aerococcus species</i>	<i>Enterococcus faecalis</i> (78)	<i>Pediococcus parvulus</i>	(54)
(includes <i>A. urinae</i> and <i>A. viridans</i>)	<i>Enterococcus faecium</i> (33)	<i>Pediococcus pentosaceus</i>	<i>Streptococcus anginosus</i> (1)
<i>Aerococcus urinae</i>	<i>Enterococcus hirae</i>	<i>Pediococcus species</i>	<i>Streptococcus bovis</i>
<i>Aerococcus viridans</i>	<i>Enterococcus raffinosus</i> (3)	(includes <i>P. dammosus</i> , <i>P. parvulus</i> and <i>P. pentosaceus</i>)	(includes <i>S. bovis</i> I and <i>S. bovis</i> II) (10)
<i>Alloiococcus otiditis</i> *	<i>Enterococcus solitarius</i>	<i>Rhodococcus equi</i>	<i>Streptococcus constellatus</i> (1)
<i>Arcanobacterium hemolyticum</i> *(2)	<i>Erysipelothrix rhusiopathiae</i>	<i>Rothia dentocariosa</i> * (1)	<i>Streptococcus cricetus</i> *
<i>Bacillus brevis</i> (1)	<i>Gardnerella vaginalis</i>	<i>Staphylococcus aureus</i> (88)	<i>Streptococcus crista</i>
<i>Bacillus cereus</i> (2)	<i>Gemella haemolysans</i>	<i>Staphylococcus aureus</i> (2)	<i>Streptococcus equi</i> (includes <i>S. equi</i> ssp <i>equi</i> and <i>S. equi</i> ssp <i>zooepidemicus</i>) (1)
<i>Bacillus circulans</i>	<i>Gemella morbillorum</i>	<i>Staphylococcus capitis</i>	<i>Streptococcus equi</i> ssp <i>equi</i> (2)
<i>Bacillus coagulans</i>	<i>Gemella species</i> (includes <i>G. haemolysans</i> and <i>G. morbillorum</i>)	(includes <i>S. capitis</i> ssp <i>capitis</i> and <i>S. capitis</i> ssp <i>ureolyticus</i>) (13)	<i>Streptococcus equi</i> ssp <i>zooepidemicus</i>
<i>Bacillus licheniformis</i> (1)	<i>Globicatella sanguis</i> (3)	<i>Staphylococcus caprae</i>	<i>Streptococcus equinus</i>
<i>Bacillus megaterium</i>	<i>Helcococcus kunzii</i>	<i>Staphylococcus carnosus</i>	<i>Streptococcus gordonii</i>
<i>Bacillus pumilus</i>	<i>Lactococcus garvieae</i>	<i>Staphylococcus cohnii</i>	<i>Streptococcus Group C/G</i>
<i>Bacillus species</i> (includes <i>B. brevis</i> , <i>B. circulans</i> , <i>B. coagulans</i> , <i>B. licheniformis</i> , <i>B. megaterium</i> , <i>B. pumilus</i> , and <i>B. sphaericus</i> , <i>P. alvei</i> , <i>P. macerans</i>) (9)	<i>Lactococcus lactis</i> ssp <i>cremoris</i>	(includes <i>S. cohnii</i> ssp <i>cohnii</i> and <i>S. cohnii</i> ssp <i>urealyticum</i>) (1)	(11)
<i>Bacillus sphaericus</i>	<i>Lactococcus lactis</i> ssp <i>hordniae</i>	<i>Staphylococcus cohnii</i> ssp <i>cohnii</i>	<i>Streptococcus intermedius</i>
<i>Bacillus subtilis</i> (1)	<i>Lactococcus lactis</i> ssp <i>lactis</i>	<i>Staphylococcus cohnii</i> ssp <i>urealyticum</i>	<i>Streptococcus milleri</i>
<i>Corynebacterium aquaticum</i>	<i>Lactococcus raffinolactis</i>	<i>Staphylococcus cohnii</i> ssp <i>urealyticum</i>	group (includes <i>S. anginosus</i>, <i>S. constellatus</i> and <i>S. intermedius</i>) (20)
<i>Corynebacterium bovis</i>	<i>Lactococcus species</i>	<i>Staphylococcus epidermidis</i> (88)	<i>Streptococcus mitis</i> (4)
<i>Corynebacterium diphtheriae</i> (includes <i>C. diphtheriae</i> ssp <i>gravis</i> , <i>C. diphtheriae</i> ssp <i>mitis</i> and <i>C. diphtheriae</i> ssp <i>intermedius</i>)	(includes <i>L. lactis</i> ssp <i>cremoris</i> , <i>L. lactis</i> ssp <i>hordniae</i> , <i>L. lactis</i> ssp <i>lactis</i> and <i>L. raffinolactis</i>)	<i>Staphylococcus equorum</i>	<i>Streptococcus mitis</i> group
<i>Corynebacterium diphtheriae</i>	<i>Leuconostoc citreum</i>	<i>Staphylococcus felis</i>	(includes <i>S. mitis</i> and <i>S. oralis</i>) (20)
<i>Corynebacterium diphtheriae</i>	<i>Leuconostoc lactis</i> (1)	<i>Staphylococcus gallinarum</i>	<i>Streptococcus mutans</i>
<i>Corynebacterium diphtheriae</i>	<i>Leuconostoc mesenteroides</i>	<i>Staphylococcus haemolyticus</i> (23)	<i>Streptococcus mutans</i> group (includes <i>S. cricetus</i> , <i>S. mutans</i> and <i>S. sobrinus</i>) (2)
<i>Corynebacterium diphtheriae</i>	ssp <i>mesenteroides</i>	<i>Staphylococcus hominus</i> (17)	<i>Streptococcus oralis</i>
<i>Corynebacterium diphtheriae</i>	<i>Leuconostoc pseudomesenteroides</i>	<i>Staphylococcus intermedius</i>	<i>Streptococcus parasanguis</i> (1)
<i>Corynebacterium genitalium</i>	<i>Leuconostoc species</i>	<i>Staphylococcus kloosii</i> (2)	<i>Streptococcus pneumoniae</i> (54)
<i>Corynebacterium jeikeium</i> (7)	(includes <i>L. citreum</i> , <i>L. lactis</i> , <i>L. mesenteroides</i> ssp <i>mesenteroides</i> and <i>L. pseudomesenteroides</i>)	<i>Staphylococcus lentus</i>	<i>Streptococcus porcinus</i>
<i>Corynebacterium kutscheri</i>	<i>Listeria grayi</i> *	<i>Staphylococcus lugdunensis</i> (3)	<i>Streptococcus pyogenes</i>
<i>Corynebacterium propinquum</i> (1)	<i>Listeria ivanovii</i> ssp <i>ivanovii</i>	<i>Staphylococcus pasteurii</i> * (1)	(50)
<i>Corynebacterium pseudodiphtheriticum</i> (2)	<i>Listeria monocytogenes</i> (3)	<i>Staphylococcus saccharolyticus</i> (6)	<i>Streptococcus salivarius</i> (3)
<i>Corynebacterium pseudogenitalium</i>	<i>Listeria murrayi</i>	<i>Staphylococcus saprophyticus</i>	<i>Streptococcus salivarius</i> group (includes <i>S. salivarius</i> and <i>S. vestibularis</i>) (4)
<i>Corynebacterium pseudotuberculosis</i> (2)	<i>Micrococcus kristinae</i>	<i>Staphylococcus schleiferi</i>	<i>Streptococcus sanguis</i> (2)
<i>Corynebacterium renale</i> group	<i>Micrococcus luteus</i>	(includes <i>S. schleiferi</i> ssp <i>coagulans</i> and <i>S. schleiferi</i> ssp <i>schleiferi</i>)	<i>Streptococcus sanguis</i> group (includes <i>S. crista</i> , <i>S. gordonii</i> , <i>S. parasanguis</i> and <i>S. sanguis</i>)
<i>Corynebacterium species</i>	<i>Micrococcus lylae</i>	<i>Staphylococcus sciuri</i>	<i>Streptococcus sobrinus</i>
(includes <i>C. aquaticum</i>, <i>C. bovis</i>, <i>C. kutscheri</i>, <i>C. propinquum</i>, <i>C. pseudodiphtheriticum</i>, <i>C. pseudotuberculosis</i>, <i>C. renale</i> group, <i>C. striatum</i> and <i>C. ulcerans</i>) (29)	<i>Micrococcus roseus</i>	<i>Staphylococcus simulans</i> (3)	<i>Streptococcus uberis</i>
<i>Corynebacterium striatum</i> (6)	<i>Micrococcus sedentarius</i>	<i>Staphylococcus vitulus</i>	<i>Streptococcus vestibularis</i>
<i>Corynebacterium ulcerans</i>	<i>Micrococcus species</i>	<i>Staphylococcus warneri</i> (6)	<i>Turicella otiditis</i> *
<i>Enterococcus avium</i> (3)	(includes <i>M. kristinae</i>, <i>M. luteus</i>, <i>M. lylae</i>, <i>M. roseus</i> and <i>M. sedentarius</i>) (10)	<i>Staphylococcus xylosum</i> (1)	
<i>Enterococcus casseliflavus/gallinarum</i> (14)	<i>Oerskovia species</i> (includes <i>O. turbata</i> and <i>O. xanthineolytica</i>)	<i>Stomatococcus mucilaginosus</i> (6)	
	<i>Paenibacillus alvei</i>	<i>Streptococcus acidominimus</i>	
	<i>Paenibacillus macerans</i>		

Key: Table 1

- KEY: * = These taxa have fewer than 10 unique **BBL CRYSTAL** profiles in the current database.
- ("X") = Number of isolates (i.e., "x") encountered in the clinical trial. If no number in parenthesis is shown after an organism name or group description, these species were not encountered in the clinical trial.
- Note #1: There were 14 additional isolates encountered in the clinical trial that are not shown above. Five (5) (i.e., 4 *Staphylococcus* species and 1 *Enterococcus*) were identified only to the genus level by the reference system against which **BBL CRYSTAL** GP was compared, although **BBL CRYSTAL** GP identified these organisms to the species level. Nine (9) were identified by the reference system, but were not included in the **BBL CRYSTAL** GP database taxa.
- Note #2: The organisms shown in bold face type were encountered 10 or more times in the clinical study for this product.
- Note #3: The organisms not shown in bold face type are either species which are rarely isolated from human clinical specimens or species that were infrequently (less than 10) encountered in the clinical study for this product. The laboratorian should determine if additional testing is required to confirm their identity.

Table 2
Principles of Tests Employed in the BBL CRYSTAL™ GP
ID System

Panel Location	Test Feature	Code	Principle (Reference)
4A	Fluorescent negative control	FCT	Control to standardize fluorescent substrate results.
2A	4MU-β-D-glucoside	FGC	Enzymatic hydrolysis of the amide or glycosidic bond results in the release of a fluorescent coumarin derivative. ^{5,8,11,12,14,15}
1A	L-valine-AMC	FVA	
4B	L-phenylalanine-AMC	FPH	
2B	4MU-α-D-glucoside	FGS	
1B	L-pyroglutamic acid-AMC	FPY	
4C	L-tryptophan-AMC	FTR	
2C	L-arginine-AMC	FAR	
1C	4MU-N-acetyl-β-D-glucosaminide	FGA	
4D	4MU-phosphate	FHO	
2D	4MU-β-D-glucuronide	FGN	
1D	L-isoleucine-AMC	FIS	
4E	Trehalose	TRE	Utilization of carbohydrate results in lower pH and change in indicator (Phenol red). ^{1,2,3,4,7,16}
2E	Lactose	LAC	
1E	Methyl-α & β-glucoside	MAB	
4F	Sucrose	SUC	
2F	Mannitol	MNT	
1F	Maltotriose	MTT	
4G	Arabinose	ARA	
2G	Glycerol	GLR	
1G	Fructose	FRU	
4H	p-nitrophenyl-β-D-glucoside	BGL	Enzymatic hydrolysis of the colorless aryl substituted glycoside releases yellow p-nitrophenol. ^{5,9,12}
2H	p-nitrophenyl-β-D-cellobioside	PCE	
1H	Proline & Leucine-p-nitroanilide	PLN	Enzymatic hydrolysis of the colorless aryl substituted glycoside releases yellow p-nitroaniline. ^{5,9,12}
4I	p-nitrophenyl-phosphate	PHO	Enzymatic hydrolysis of the colorless aryl substituted glycoside releases yellow p-nitrophenol. ^{5,9,12}
2I	p-nitrophenyl-α-D-maltoside	PAM	
1I	o-nitrophenyl-β-D-galactoside (ONPG) & p-nitrophenyl-α-D-galactoside	PGO	
4J	Urea	URE	Hydrolysis of urea and the resulting ammonia change the pH indicator color (Bromthymol blue). ^{2,6,10}
2J	Esculin	ESC	Hydrolysis of esculin results in a black precipitate in the presence of ferric ion. ¹⁰
1J	Arginine	ARG	Utilization of arginine results in pH rise and change in the color of the indicator (Bromcresol purple). ²

Table 3
Reagents used in the BBL CRYSTAL™ GP ID
System

Panel Location	Substrate	Code	Pos.	Neg.	Active Ingredients	Approx. Amt. (g/L)
4A	Fluorescent negative control	FCT	n/a	n/a	Fluorescent coumarin derivative	≤1
2A	4MU-β-D-glucoside	FGC	blue fluorescence >FCT well	blue fluorescence ≤FCT well	4MU-β-D-glucoside	≤1
1A	L-valine-AMC	FVA	blue fluorescence >FCT well	blue fluorescence ≤FCT well	L-valine-AMC	≤1
4B	L-phenylalanine-AMC	FPH	blue fluorescence >FCT well	blue fluorescence ≤FCT well	L-phenylalanine-AMC	≤1
2B	4MU-α-D-glucoside	FGS	blue fluorescence >FCT well	blue fluorescence ≤FCT well	4MU-α-D-glucoside	≤1
1B	L-pyroglutamic acid-AMC	FPY	blue fluorescence >FCT well	blue fluorescence ≤FCT well	L-pyroglutamic acid-AMC	≤1
4C	L-tryptophan-AMC	FTR	blue fluorescence >FCT well	blue fluorescence ≤FCT well	L-tryptophan-AMC	≤1
2C	L-arginine-AMC	FAR	blue fluorescence >FCT well	blue fluorescence ≤FCT well	L-arginine-AMC	≤1
1C	4MU-N-acetyl-β-D-glucosaminide	FGA	blue fluorescence >FCT well	blue fluorescence ≤FCT well	4MU-N-acetyl-β-D-glucosaminide	≤1
4D	4MU-phosphate	FHO	blue fluorescence >FCT well	blue fluorescence ≤FCT well	4MU-phosphate	≤1
2D	4MU-β-D-glucuronide	FGN	blue fluorescence >FCT well	blue fluorescence ≤FCT well	4MU-β-D-glucuronide	≤1
1D	L-isoleucine-AMC	FIS	blue fluorescence >FCT well	blue fluorescence ≤FCT well	L-isoleucine-AMC	≤1
4E	Trehalose	TRE	Gold/Yellow	Orange/Red	Trehalose	≤300
2E	Lactose	LAC	Gold/Yellow	Orange/Red	Lactose	≤300
1E	Methyl-α & β-glucoside	MAB	Gold/Yellow	Orange/Red	Methyl-α & β-glucoside	≤300
4F	Sucrose	SUC	Gold/Yellow	Orange/Red	Sucrose	≤300
2F	Mannitol	MNT	Gold/Yellow	Orange/Red	Mannitol	≤300
1F	Maltotriose	MTT	Gold/Yellow	Orange/Red	Maltotriose	≤300
4G	Arabinose	ARA	Gold/Yellow	Orange/Red	Arabinose	≤300
2G	Glycerol	GLR	Gold/Yellow	Orange/Red	Glycerol	≤300
1G	Fructose	FRU	Gold/Yellow	Orange/Red	Fructose	≤300
4H	p-n-p-β-D-glucoside	BGL	Yellow	Colorless	p-n-p-β-D-glucoside	≤10
2H	p-n-p-β-D-cellobioside	PCE	Yellow	Colorless	p-n-p-β-D-cellobioside	≤10
1H	Proline & Leucine-p-nitroanilide	PLN	Yellow	Colorless	Proline & Leucine-p-nitroanilide	≤10
4I	p-n-p-phosphate	PHO	Yellow	Colorless	p-n-p-phosphate	≤10
2I	p-n-p-α-D-maltoside	PAM	Yellow	Colorless	p-n-p-α-D-maltoside	≤10
1I	ONPG & p-n-p-α-D-galactoside	PGO	Yellow	Colorless	ONPG & p-n-p-α-D-galactoside	≤10
4J	Urea	URE	Aqua/Blue	Yellow/Green	Urea	≤50
2J	Esculin	ESC	Brown/Maroon	Clear/Tan	Esculin	≤25
1J	Arginine	ARG	Purple	Yellow/Gray	Arginine	≤200

Table 4
Quality Control Chart for BBL CRYSTAL™ GP ID System
After 18 – 20 Hours Incubation from TSAII™ or
Columbia Blood Agar

Panel Location	Substrate	Code	<i>Streptococcus pyogenes</i> ATCC 19615
4A	Fluorescent negative control	FCT	–
2A	4 MU-β-D-glucoside	FGC	–
1A	L-valine-AMC	FVA	+
4B	L-phenylalanine-AMC	FPH	+
2B	4MU-α-D-glucoside	FGS	+
1B	L-pyroglutamic acid-AMC	FPY	+
4C	L-tryptophan-AMC	FTR	+
2C	L-arginine-AMC	FAR	+
1C	4MU-N-acetyl-β-D-glucosaminide	FGA	–
4D	4MU-phosphate	FHO	+
2D	4MU-β-D-glucuronide	FGN	–
1D	L-isoleucine-AMC	FIS	+
4E	Trehalose	TRE	+
2E	Lactose	LAC	+
1E	Methyl-α & β glucoside	MAB	+
4F	Sucrose	SUC	+
2F	Mannitol	MNT	–
1F	Maltotriose	MTT	+
4G	Arabinose	ARA	–
2G	Glycerol	GLR	+
1G	Fructose	FRU	+
4H	p-n-p-β-D-glucoside	BGL	V
2H	p-n-p-β-D-cellobioside	PCE	–
1H	Proline & Leucine-p-nitroanilide	PLN	+
4I	p-n-p-phosphate	PHO	V
2I	p-n-p-α-D-maltoside	PAM	–*
1I	ONPG & p-n-p-α-D-galactoside	PGO	–
4J	Urea	URE	–
2J	Esculin	ESC	–
1J	Arginine	ARG	V

* = variable when tested from Columbia Blood Agar

Table 5
Additional Quality Control Strains for BBL CRYSTAL™ GP ID System
After 18 – 20 Hours Incubation from TSA II™ or Columbia Blood Agar

Panel Location	Substrate	Code	<i>Staphylococcus epidermidis</i> ATCC 12228	<i>Bacillus brevis</i> ATCC 8246	<i>Enterococcus faecalis</i> ATCC 19433	<i>Staphylococcus xylosus</i> ATCC 35033
4A	Fluorescent negative control	FCT	–	–	–	–
2A	4 MU-β-D-glucoside	FGC	–	+	+	–
1A	L-valine-AMC	FVA	–	+	–	–
4B	L-phenylalanine-AMC	FPH	–	+	+	–
2B	4MU-α-D-glucoside	FGS	–*	+	+	–
1B	L-pyroglutamic acid-AMC	FPY	–	+	+	V
4C	L-tryptophan-AMC	FTR	–	+	+	V
2C	L-arginine-AMC	FAR	V	+	–	–
1C	4MU-N-acetyl-β-D-glucosaminide	FGA	–	+	+	–
4D	4MU-phosphate	FHO	+	V	V	+
2D	4MU-β-D-glucuronide	FGN	–	–	–	+
1D	L-isoleucine-AMC	FIS	–	V	–	–
4E	Trehalose	TRE	–	–	+	+
2E	Lactose	LAC	+	–	+	+
1E	Methyl-α & β glucoside	MAB	–	–	+	+
4F	Sucrose	SUC	+	–	+	+
2F	Mannitol	MNT	–	–	+	+
1F	Maltotriose	MTT	+	–	+	–*
4G	Arabinose	ARA	–	–	–	V
2G	Glycerol	GLR	+	–	+	+
1G	Fructose	FRU	+	–	+	+
4H	p-n-p-β-D-glucoside	BGL	–	V	+	+
2H	p-n-p-β-D-cellobioside	PCE	–	–	+	–
1H	Proline & Leucine-p-nitroanilide	PLN	V	V	–	–
4I	p-n-p-phosphate	PHO	V	V	V	+
2I	p-n-p-α-D-maltoside	PAM	–*	V	+	–*
1I	ONPG & p-n-p-α-D-galactoside	PGO	V	–	–	V
4J	Urea	URE	+	V	V	+
2J	Esculin	ESC	–	V	+	–
1J	Arginine	ARG	V	+	+	V

* = variable when tested from Columbia Blood Agar

Table 6
Expected Reactions for Species Most Frequently Encountered in BBL CRYSTAL™ GP ID System Clinical Trials

Organisms	FCT	FGC	FVA	FPH	FGS	FPY	FTR	FAR	FGA	FHO	FGN	FIS	TRE	LAC	MAB	SUC	MNT	MTT	ARA	GLR	FRU	BGL	PCE	PLN	PHO	PAM	PGO	URE	ESC	ARO
<i>E. faecalis</i>	-	+	-	+	+	+	+	-	+	-	-	-	+	V	+	(+)	+	+	V	+	+	+	+	-	V	+	-	(-)	+	+
<i>E. faecium</i>	-	+	-	+	(-)	+	+	+	-	-	-	-	+	+	V	(+)	+	+	+	V	+	+	+	-	(-)	+	(+)	-	+	+
<i>S. aureus</i>	-	-	-	-	-	(-)	V	+	-	+	-	-	(+)	V	(+)	+	+	+	-	+	+	(+)	-	-	+	V	-	-	-	(+)
<i>S. capitis</i>	-	-	-	-	-	-	-	V	-	(-)	-	-	-	-	-	-	V	-	-	+	(+)	-	-	-	V	-	-	-	-	(+)
<i>S. epidermidis</i>	-	-	-	-	-	-	-	(-)	-	+	-	-	-	+	-	+	-	+	-	+	+	(-)	-	V	(+)	V	(-)	+	-	V
<i>S. haemolyticus</i>	-	-	-	-	-	+	-	(-)	V	-	(-)	-	(+)	V	(-)	+	V	+	-	+	(+)	V	-	-	V	V	(-)	-	-	V
<i>S. hominis</i>	-	-	-	-	-	-	-	V	-	-	-	-	V	V	-	V	-	(+)	-	+	+	(-)	-	V	V	V	(-)	+	-	-
<i>S. agalactiae</i>	-	-	V	+	(+)	-	+	+	-	+	V	V	+	V	+	+	V	+	-	V	+	(+)	-	V	+	-	(-)	-	-	V
<i>S. bovis</i>	-	+	+	+	+	-	+	V	V	-	V	+	(+)	+	+	+	V	+	-	-	+	+	+	(+)	V	-	+	-	+	-
<i>S. pneumoniae</i>	-	V	+	+	+	-	+	+	+	-	-	+	-	-	-	-	-	-	-	-	-	-	V	V	(+)	-	V	+	-	(-)
<i>S. pyogenes</i>	-	-	+	+	V	+	+	+	-	+	(-)	+	+	+	+	+	-	+	-	+	+	V	-	(+)	+	(-)	-	-	V	V

KEY: + = ≥ 90% positive; (+) = 75 – 89% positive; V = 26 – 74% positive; (-) = 11 – 25% positive; - = ≤ 10% positive.

Table 7
Accuracy of Identification for Species Most Frequently Encountered
in BBL CRYSTAL™ GP ID System Clinical Trial

Organism	Number Tested	BBL CRYSTAL Correct ID	BBL CRYSTAL correct w/supplemental tests	Total Correct
<i>Corynebacterium</i> species	29	29	0	29
<i>Enterococcus casseliflavus/gallinarum</i>	14	0	14 ¹	14
<i>Enterococcus faecalis</i>	78	78	0	78
<i>Enterococcus faecium</i>	33	30	3	33
<i>Micrococcus</i> species	10	10	0	10
<i>Staphylococcus aureus</i>	88	85	3	88
<i>Staphylococcus capitis</i>	13	13	0	13
<i>Staphylococcus epidermidis</i>	87	87	0	87
<i>Staphylococcus haemolyticus</i>	23	23	0	23
<i>Staphylococcus hominis</i>	17	10	1	11
<i>Streptococcus agalactiae</i>	54	49	2	51
<i>Streptococcus bovis</i>	10	8	1	9
<i>Streptococcus mitteri</i> group	20	18	2	20
<i>Streptococcus mitis</i> group ²	23	8	1	9
<i>Streptococcus pneumoniae</i>	54	45	8	53
<i>Streptococcus pyogenes</i>	50	49	0	49
Other*	132	81	10	91
Grand Total	735	623	45	668

Key: * = This category comprises all isolates where less than 10 were encountered in clinical trials.
1 = Colony pigmentation is the sole supplemental test required to obtain correct identification.
2 = As follow-up to this group's accuracy results, remedial actions were subsequently implemented to improve performance.